GSK-217744/085 (DTPa-Hep B-IPV-085)

A phase III, open labeled, randomized, multicenter, clinical study of the safety and immunogenicity of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepBIPV candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared to the separate administration of Infanrix® + Engerix-B® + IPOL® + HibTITER + Prevnar and to GSK Biologicals' DTaP-HepB-IPV candidate vaccine coadministered with HibTITER
Combined Diphtheria, Tetanus, Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), Inactivated Polio Vaccine
217744/085 (DTPa-Hep B-IPV-085)
Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013